Diagnosis and treatment options of neuroendocrine tumours

被引:1
作者
Uhlyarik Andrea [1 ]
Papai Zsuzsanna [1 ]
机构
[1] Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary
关键词
neuroendocrine tumour; endocrine syndrome; chromogranin A; diagnostic imaging; therapy; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; ENETS CONSENSUS GUIDELINES; NEURON-SPECIFIC ENOLASE; LIVER METASTASES; RADIOFREQUENCY ABLATION; PROGNOSTIC-FACTORS; CHROMOGRANIN-A; CARCINOIDS; STANDARDS; SURVIVAL;
D O I
10.1556/OH.2013.29716
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Neuroendocrine neoplasms belong to the group of rare tumours. Their clinical importance may be highlighted by their high prevalence despite low incidence. Since survival rate is similar to other progressive neoplastic diseases in metastatic cases, early recognition and appropriate therapy of these neoplasms are equally important. Classification of neuroendocrine tumours is based on their pathologic characteristics according to the 2010 WHO recommendation. Non-functioning tumours cause local symptoms due to their mass effect, while functioning tumours produce well-defined endocrine syndromes. Among laboratory tests, serum chromogranin-A is considered the most important biomarker of both non-functioning and functioning neuroendocrine tumours. Localization of these tumours includes the use of conventional diagnostic imaging, endoscopic examinations, and functional imaging studies. With respect to treatment, elimination of the primary tumour remains one of the most important issues. In advanced cases of the disease metastasectomy, interventional radiologic methods, medical treatment and endoradiotherapy can be used. The aim of this review is to summarize briefly the symptoms, diagnostic methods and treatment options of neuroendocrine tumours.
引用
收藏
页码:1549 / 1555
页数:7
相关论文
共 33 条
[1]  
[Anonymous], 2010, WHO CLASSIFICATION T
[2]  
Balon HR, 2001, J NUCL MED, V42, P1134
[3]   Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours [J].
Baudin, E ;
Gigliotti, A ;
Ducreux, R ;
Ropers, J ;
Comoy, E ;
Sabourin, JC ;
Bidart, JM ;
Cailleux, AF ;
Bonacci, R ;
Ruffié, P ;
Schlumberger, M .
BRITISH JOURNAL OF CANCER, 1998, 78 (08) :1102-1107
[4]   Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET [J].
Binderup, Tina ;
Knigge, Ulrich ;
Loft, Annika ;
Mortensen, Jann ;
Pfeifer, Andreas ;
Federspiel, Birgitte ;
Hansen, Carsten Palnaes ;
Hojgaard, Liselotte ;
Kjaer, Andreas .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (05) :704-712
[5]  
Clark OH, 2009, J NATL COMPR CANC NE, V7, P712
[6]   Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging [J].
Dromain, C ;
de Baere, T ;
Lumbroso, J ;
Caillet, H ;
Laplanche, AS ;
Boige, V ;
Ducreux, M ;
Duvillard, P ;
Elias, D ;
Schlumberger, M ;
Sigal, R ;
Baudin, E .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :70-78
[7]   Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors [J].
Eriksson, John ;
Stalberg, Peter ;
Nilsson, Anders ;
Krause, Johan ;
Lundberg, Christina ;
Skogseid, Britt ;
Granberg, Dan ;
Eriksson, Barbro ;
Akerstom, Goran ;
Hellman, Per .
WORLD JOURNAL OF SURGERY, 2008, 32 (05) :930-938
[8]   Pulmonary carcinoid - Presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature [J].
Fink, G ;
Krelbaum, T ;
Yellin, A ;
Bendayan, D ;
Saute, M ;
Glazer, M ;
Kramer, MR .
CHEST, 2001, 119 (06) :1647-1651
[9]   Neuroendocrine tumors of the diffuse neuroendocrine system [J].
Gustafsson, Bjorn I. ;
Kidd, Mark ;
Modlin, Irvin M. .
CURRENT OPINION IN ONCOLOGY, 2008, 20 (01) :1-12
[10]  
Igaz P., 2009, LAM, V19, P493